Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos
  3. ESMO Videos

ASCO 2019: Highlights on results from the KEYNOTE 062 study

Reporting from ASCO 2019, J. Tabernero details the study results from the KEYNOTE-062 in advanced gastric or gastro-oesophageal junction adenocarcinoma that tested pembrolizumab vs chemotherapy vs their combination. Additional data analysis is ongoing to identify the populations who responded best to pembrolizumab.

LBA4007: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study, Josep Tabernero

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.